First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients
Fecha
2022Language
en
Materia
Resumen
Background/Aims: As previous real-world studies and meta-analyses have shown that mycophenolate mofetil (MMF) might have better efficacy than azathioprine (AZA) in autoimmune hepatitis (AIH), we conducted a propensity matching study to assess the efficacy and safety of MMF vs. AZA. Methods: All 126 consecutive treatment-naive adult AIH patients, diagnosed and followed in our department since 2016, were included. Patients received prednisolone 0.5–1 mg/kg/day plus either AZA 1–2 mg/kg/day or 1.5–2 g/day MMF. The tapering of prednisolone was identical between groups. Results: After propensity matching score and adjustment for known factors affecting response to treatment and outcome, 64 patients were included in the study (MMF = 32 and AZA = 32). Rates of non-response, complete biochemical response (CBR) at 6 and 12 months, and prednisolone withdrawal (6 months, 12 months, and end of follow-up) were identical between groups. However, MMF treatment was significantly associated with CBR at the end of follow-up [odds ratio (OR) 11.259; 95% CI: 1.3–97.4, p = 0.028]. AZA patients were more prone to stop treatment due to AZA intolerance/insufficient response (p = 0.0001). At the end of follow-up, the overall efficacy of each schedule was also significantly higher in the MMF group compared to the AZA group (p = 0.0001). Conclusion: We showed for the first time in a propensity matching study that MMF can be used as first-line therapy in AIH as attested by the significantly higher CBR at end of follow-up compared to AZA. Whether this better efficacy is also associated with higher histological remission rates and sustained CBR off immunosuppression needs further evaluation. Copyright © 2022 Dalekos, Arvaniti, Gatselis, Samakidou, Gabeta, Rigopoulou, Koukoulis and Zachou.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1
Agrawal R., Gunasekeran D.V., Grant R., Agarwal A., Kon O.M., Nguyen Q.D., Pavesio C., Gupta V., Gupta B., Aggarwal K., Murthy S.L., Westcott M., Phaik C.S., McCluskey P., Ling H.S., Teoh S., Cimino L., Biswas J., Narain S., Agarwal M., Mahendradas P., Khairallah M., Jones N., Tugal-Tutkun I., Babu K., Basu S., Carreño E., Lee R., Al-Dhibi H., Bodaghi B., Invernizzi A., Goldstein D.A., Herbort C.P., Barisani T., González-López J.J., Androudi S., Bansal R., Moharana B., Mahajan S., Esposti S., Tasiopoulou A., Nadarajah S., Agarwal M., Abraham S., Vala R., Singh R., Sharma A., Sharma K., Zierhut M., Raje D., Cunningham E., Kempen J., Collaborative Ocular Tuberculosis Study (COTS)-1 Study Group (2017)IMPORTANCE Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HIV pandemic. Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the existing ... -
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes
Diamantopoulos P.T., Symeonidis A., Pappa V., Kotsianidis I., Galanopoulos A., Pontikoglou C., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Repousis P., Kotsopoulou M., Dimou M., Solomou E., Dryllis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kyrtshonis M.-C., Kourakli A., Papadaki H., Panayiotidis P., Viniou N.-A. (2021)The regimen of 5-azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common ... -
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
Bawazeer G.A., Alkofide H.A., Alsharafi A.A., Babakr N.O., Altorkistani A.M., Kashour T.S., Miligkos M., AlFaleh K.M., Al-Ansary L.A. (2021)Background: The management of anticoagulation therapy around the time of catheter ablation (CA) procedure for adults with arrhythmia is critical and yet is variable in clinical practice. The ideal approach for safe and ...